nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—RRM2—Hydroxyurea—psoriasis	0.326	0.453	CbGbCtD
Cladribine—RRM1—Hydroxyurea—psoriasis	0.326	0.453	CbGbCtD
Cladribine—ABCG2—Mycophenolate mofetil—psoriasis	0.0194	0.027	CbGbCtD
Cladribine—ABCG2—Hydrocortisone—psoriasis	0.0156	0.0217	CbGbCtD
Cladribine—ABCG2—Cyclosporine—psoriasis	0.0147	0.0205	CbGbCtD
Cladribine—ABCG2—Dexamethasone—psoriasis	0.00968	0.0135	CbGbCtD
Cladribine—ABCG2—Methotrexate—psoriasis	0.00778	0.0108	CbGbCtD
Cladribine—PNP—Purine catabolism—CAT—psoriasis	0.0043	0.0633	CbGpPWpGaD
Cladribine—POLE4—skin of body—psoriasis	0.00194	0.245	CbGeAlD
Cladribine—POLE2—Repair synthesis for gap-filling by DNA polymerase in TC-NER—PCNA—psoriasis	0.00189	0.0278	CbGpPWpGaD
Cladribine—POLE2—Gap-filling DNA repair synthesis and ligation in GG-NER—PCNA—psoriasis	0.00171	0.0251	CbGpPWpGaD
Cladribine—PNP—Purine metabolism—CAT—psoriasis	0.00165	0.0244	CbGpPWpGaD
Cladribine—POLE2—Telomere C-strand (Lagging Strand) Synthesis—PCNA—psoriasis	0.00134	0.0197	CbGpPWpGaD
Cladribine—POLE2—tendon—psoriasis	0.00129	0.163	CbGeAlD
Cladribine—NR5A1—Ovarian Infertility Genes—VDR—psoriasis	0.00122	0.018	CbGpPWpGaD
Cladribine—POLE—Repair synthesis for gap-filling by DNA polymerase in TC-NER—PCNA—psoriasis	0.00122	0.0179	CbGpPWpGaD
Cladribine—RRM2—G1/S-Specific Transcription—PCNA—psoriasis	0.00115	0.0169	CbGpPWpGaD
Cladribine—POLE2—Extension of Telomeres—PCNA—psoriasis	0.00111	0.0164	CbGpPWpGaD
Cladribine—POLE—Gap-filling DNA repair synthesis and ligation in GG-NER—PCNA—psoriasis	0.0011	0.0162	CbGpPWpGaD
Cladribine—NR5A1—Nuclear Receptors—VDR—psoriasis	0.00107	0.0157	CbGpPWpGaD
Cladribine—POLE2—Global Genomic NER (GG-NER)—PCNA—psoriasis	0.00098	0.0144	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—TGFA—psoriasis	0.000976	0.0144	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—CARM1—psoriasis	0.000976	0.0144	CbGpPWpGaD
Cladribine—RRM2B—Nucleotide metabolism—CAT—psoriasis	0.000958	0.0141	CbGpPWpGaD
Cladribine—POLA1—Leading Strand Synthesis—PCNA—psoriasis	0.000915	0.0135	CbGpPWpGaD
Cladribine—POLA1—Removal of the Flap Intermediate—PCNA—psoriasis	0.000915	0.0135	CbGpPWpGaD
Cladribine—POLE—Telomere C-strand (Lagging Strand) Synthesis—PCNA—psoriasis	0.000863	0.0127	CbGpPWpGaD
Cladribine—NR5A1—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000842	0.0124	CbGpPWpGaD
Cladribine—PNP—Nucleotide metabolism—CAT—psoriasis	0.000831	0.0122	CbGpPWpGaD
Cladribine—POLE2—DNA Replication—PCNA—psoriasis	0.000828	0.0122	CbGpPWpGaD
Cladribine—POLA1—Processive synthesis on the lagging strand—PCNA—psoriasis	0.000822	0.0121	CbGpPWpGaD
Cladribine—POLA1—G1/S-Specific Transcription—PCNA—psoriasis	0.000784	0.0115	CbGpPWpGaD
Cladribine—POLE2—Transcription-coupled NER (TC-NER)—PCNA—psoriasis	0.000783	0.0115	CbGpPWpGaD
Cladribine—RRM2B—tendon—psoriasis	0.000756	0.0957	CbGeAlD
Cladribine—NR5A1—Nuclear Receptors—PPARG—psoriasis	0.000743	0.0109	CbGpPWpGaD
Cladribine—NR5A1—Transcriptional regulation of pluripotent stem cells—STAT3—psoriasis	0.000732	0.0108	CbGpPWpGaD
Cladribine—DCK—Purine metabolism—CAT—psoriasis	0.000731	0.0108	CbGpPWpGaD
Cladribine—POLE2—Nucleotide Excision Repair—PCNA—psoriasis	0.00072	0.0106	CbGpPWpGaD
Cladribine—POLE—Extension of Telomeres—PCNA—psoriasis	0.000717	0.0106	CbGpPWpGaD
Cladribine—POLE3—tendon—psoriasis	0.000715	0.0905	CbGeAlD
Cladribine—RRM2—E2F mediated regulation of DNA replication—PCNA—psoriasis	0.000674	0.00993	CbGpPWpGaD
Cladribine—POLA1—Lagging Strand Synthesis—PCNA—psoriasis	0.000662	0.00975	CbGpPWpGaD
Cladribine—POLE—Global Genomic NER (GG-NER)—PCNA—psoriasis	0.000632	0.0093	CbGpPWpGaD
Cladribine—POLA1—Telomere C-strand (Lagging Strand) Synthesis—PCNA—psoriasis	0.000615	0.00906	CbGpPWpGaD
Cladribine—RRM2—skin of body—psoriasis	0.00059	0.0747	CbGeAlD
Cladribine—NR5A1—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000587	0.00865	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—VDR—psoriasis	0.000583	0.00858	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—PCNA—psoriasis	0.000563	0.00829	CbGpPWpGaD
Cladribine—POLE—tendon—psoriasis	0.000545	0.069	CbGeAlD
Cladribine—POLE—DNA Replication—PCNA—psoriasis	0.000533	0.00786	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—PCNA—psoriasis	0.000517	0.00762	CbGpPWpGaD
Cladribine—POLA1—Extension of Telomeres—PCNA—psoriasis	0.000511	0.00753	CbGpPWpGaD
Cladribine—POLE—Transcription-coupled NER (TC-NER)—PCNA—psoriasis	0.000505	0.00743	CbGpPWpGaD
Cladribine—POLE2—Telomere Maintenance—PCNA—psoriasis	0.000504	0.00743	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000493	0.00726	CbGpPWpGaD
Cladribine—RRM1—skin of body—psoriasis	0.00049	0.062	CbGeAlD
Cladribine—RRM1—Nucleotide metabolism—CAT—psoriasis	0.000477	0.00703	CbGpPWpGaD
Cladribine—POLA1—DNA strand elongation—PCNA—psoriasis	0.000472	0.00696	CbGpPWpGaD
Cladribine—POLA1—tendon—psoriasis	0.00047	0.0595	CbGeAlD
Cladribine—POLE—Nucleotide Excision Repair—PCNA—psoriasis	0.000464	0.00683	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000462	0.00681	CbGpPWpGaD
Cladribine—POLA1—E2F mediated regulation of DNA replication—PCNA—psoriasis	0.000461	0.00679	CbGpPWpGaD
Cladribine—RRM2—tendon—psoriasis	0.000449	0.0568	CbGeAlD
Cladribine—POLE2—Synthesis of DNA—PCNA—psoriasis	0.000427	0.00629	CbGpPWpGaD
Cladribine—POLE2—Chromosome Maintenance—PCNA—psoriasis	0.00042	0.00619	CbGpPWpGaD
Cladribine—ABCG2—Iron uptake and transport—CP—psoriasis	0.000403	0.00594	CbGpPWpGaD
Cladribine—POLE2—DNA Replication—PCNA—psoriasis	0.000401	0.0059	CbGpPWpGaD
Cladribine—RRM2—Nucleotide metabolism—CAT—psoriasis	0.000393	0.00579	CbGpPWpGaD
Cladribine—POLE2—Mitotic M-M/G1 phases—PTTG1—psoriasis	0.000391	0.00576	CbGpPWpGaD
Cladribine—POLE2—G1/S Transition—PCNA—psoriasis	0.000386	0.00568	CbGpPWpGaD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000381	0.00561	CbGpPWpGaD
Cladribine—POLA1—DNA Replication—PCNA—psoriasis	0.00038	0.0056	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000377	0.00555	CbGpPWpGaD
Cladribine—POLE2—DNA Repair—PCNA—psoriasis	0.000375	0.00552	CbGpPWpGaD
Cladribine—RRM1—tendon—psoriasis	0.000373	0.0472	CbGeAlD
Cladribine—NR5A1—Gene Expression—TARS—psoriasis	0.000373	0.00549	CbGpPWpGaD
Cladribine—DCK—Nucleotide metabolism—CAT—psoriasis	0.000367	0.00541	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—PCNA—psoriasis	0.000363	0.00534	CbGpPWpGaD
Cladribine—POLE2—S Phase—PCNA—psoriasis	0.00035	0.00516	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—NDUFA5—psoriasis	0.000341	0.00502	CbGpPWpGaD
Cladribine—RRM2B—DNA Damage Response—TP53—psoriasis	0.000339	0.00499	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—psoriasis	0.000327	0.00482	CbGpPWpGaD
Cladribine—POLE2—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000325	0.00479	CbGpPWpGaD
Cladribine—POLE—Telomere Maintenance—PCNA—psoriasis	0.000325	0.00479	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.00031	0.00457	CbGpPWpGaD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—psoriasis	0.000301	0.00443	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000298	0.00439	CbGpPWpGaD
Cladribine—PNP—Metabolism—NDUFA5—psoriasis	0.000295	0.00435	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000293	0.00431	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.00029	0.00427	CbGpPWpGaD
Cladribine—DCK—tendon—psoriasis	0.00029	0.0367	CbGeAlD
Cladribine—RRM2B—Metabolism—CYP2S1—psoriasis	0.00029	0.00427	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—JUN—psoriasis	0.000288	0.00424	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000286	0.00422	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000278	0.00409	CbGpPWpGaD
Cladribine—POLE—Synthesis of DNA—PCNA—psoriasis	0.000275	0.00406	CbGpPWpGaD
Cladribine—POLE—Chromosome Maintenance—PCNA—psoriasis	0.000271	0.00399	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—PTTG1—psoriasis	0.000262	0.00385	CbGpPWpGaD
Cladribine—RRM2—G1/S Transition—PCNA—psoriasis	0.000259	0.00382	CbGpPWpGaD
Cladribine—POLE—DNA Replication—PCNA—psoriasis	0.000258	0.0038	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—PTTG1—psoriasis	0.000252	0.00371	CbGpPWpGaD
Cladribine—PNP—Metabolism—CYP2S1—psoriasis	0.000251	0.0037	CbGpPWpGaD
Cladribine—POLE—G1/S Transition—PCNA—psoriasis	0.000249	0.00366	CbGpPWpGaD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—psoriasis	0.000248	0.00365	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—CARM1—psoriasis	0.000244	0.00359	CbGpPWpGaD
Cladribine—POLE—DNA Repair—PCNA—psoriasis	0.000242	0.00356	CbGpPWpGaD
Cladribine—POLA1—Telomere Maintenance—PCNA—psoriasis	0.000232	0.00341	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—CARM1—psoriasis	0.000229	0.00338	CbGpPWpGaD
Cladribine—POLE—S Phase—PCNA—psoriasis	0.000226	0.00333	CbGpPWpGaD
Cladribine—RRM2—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000218	0.00322	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000212	0.00313	CbGpPWpGaD
Cladribine—POLE—Mitotic G1-G1/S phases—PCNA—psoriasis	0.00021	0.00309	CbGpPWpGaD
Cladribine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000208	0.00307	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—TP53—psoriasis	0.000207	0.00305	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000201	0.00296	CbGpPWpGaD
Cladribine—PNP—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.0002	0.0404	CbGdCrCtD
Cladribine—RRM2—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000196	0.00289	CbGpPWpGaD
Cladribine—POLA1—Synthesis of DNA—PCNA—psoriasis	0.000196	0.00289	CbGpPWpGaD
Cladribine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000194	0.00286	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—CP—psoriasis	0.000193	0.00285	CbGpPWpGaD
Cladribine—POLA1—Chromosome Maintenance—PCNA—psoriasis	0.000193	0.00284	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—TP53—psoriasis	0.00019	0.0028	CbGpPWpGaD
Cladribine—PNP—Fluocinolone Acetonide—Clobetasol propionate—psoriasis	0.000189	0.0381	CbGdCrCtD
Cladribine—POLE—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000189	0.00278	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—CARM1—psoriasis	0.000185	0.00272	CbGpPWpGaD
Cladribine—POLA1—DNA Replication—PCNA—psoriasis	0.000184	0.00271	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—PTTG1—psoriasis	0.00018	0.00265	CbGpPWpGaD
Cladribine—POLA1—G1/S Transition—PCNA—psoriasis	0.000177	0.00261	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—PTTG1—psoriasis	0.000176	0.00259	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.00017	0.0025	CbGpPWpGaD
Cladribine—RRM1—Metabolism—NDUFA5—psoriasis	0.00017	0.0025	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000169	0.00249	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—PTTG1—psoriasis	0.000169	0.00248	CbGpPWpGaD
Cladribine—PNP—Clobetasol propionate—Fluocinonide—psoriasis	0.000168	0.034	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Beclomethasone—psoriasis	0.000168	0.034	CbGdCrCtD
Cladribine—PNP—Flunisolide—Fluocinonide—psoriasis	0.000166	0.0335	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Fluocinolone Acetonide—psoriasis	0.000164	0.033	CbGdCrCtD
Cladribine—PNP—Flunisolide—Fluocinolone Acetonide—psoriasis	0.000162	0.0326	CbGdCrCtD
Cladribine—POLA1—S Phase—PCNA—psoriasis	0.000161	0.00237	CbGpPWpGaD
Cladribine—PNP—Fluticasone Propionate—Fluocinonide—psoriasis	0.00016	0.0324	CbGdCrCtD
Cladribine—PNP—Fluticasone Propionate—Beclomethasone—psoriasis	0.00016	0.0324	CbGdCrCtD
Cladribine—PNP—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000156	0.0315	CbGdCrCtD
Cladribine—PNP—Fluocinolone Acetonide—Fluocinonide—psoriasis	0.000151	0.0305	CbGdCrCtD
Cladribine—PNP—Fluocinolone Acetonide—Beclomethasone—psoriasis	0.000151	0.0305	CbGdCrCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000149	0.0022	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—VDR—psoriasis	0.000145	0.00214	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CYP2S1—psoriasis	0.000144	0.00213	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CARM1—psoriasis	0.000142	0.00208	CbGpPWpGaD
Cladribine—RRM2—Metabolism—NDUFA5—psoriasis	0.00014	0.00206	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000139	0.00204	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000134	0.00198	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—TP53—psoriasis	0.000133	0.00196	CbGpPWpGaD
Cladribine—DCK—Metabolism—NDUFA5—psoriasis	0.000131	0.00192	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000131	0.00192	CbGpPWpGaD
Cladribine—PNP—Metabolism—CARM1—psoriasis	0.000123	0.00181	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000122	0.00179	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—PTTG1—psoriasis	0.00012	0.00177	CbGpPWpGaD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.00012	0.00176	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—PCNA—psoriasis	0.000119	0.00176	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP2S1—psoriasis	0.000119	0.00175	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—CARM1—psoriasis	0.000117	0.00173	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000114	0.00168	CbGpPWpGaD
Cladribine—DCK—Desoximetasone—Clobetasol propionate—psoriasis	0.000114	0.023	CbGdCrCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000113	0.00167	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000112	0.00165	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP2S1—psoriasis	0.000111	0.00164	CbGpPWpGaD
Cladribine—DCK—Diflorasone—Clobetasol propionate—psoriasis	0.000111	0.0223	CbGdCrCtD
Cladribine—NR5A1—Developmental Biology—LEP—psoriasis	0.00011	0.00161	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.00011	0.00161	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000108	0.00159	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—PCNA—psoriasis	0.000107	0.00157	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000107	0.00157	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—PPARG—psoriasis	0.000101	0.00149	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.77e-05	0.00144	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—PPARG—psoriasis	9.54e-05	0.00141	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	9.51e-05	0.0014	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—CP—psoriasis	9.46e-05	0.00139	CbGpPWpGaD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	9.27e-05	0.00136	CbGpPWpGaD
Cladribine—DCK—Desoximetasone—Beclomethasone—psoriasis	9.12e-05	0.0184	CbGdCrCtD
Cladribine—DCK—Desoximetasone—Fluocinonide—psoriasis	9.12e-05	0.0184	CbGdCrCtD
Cladribine—DCK—Desoximetasone—Fluocinolone Acetonide—psoriasis	8.87e-05	0.0179	CbGdCrCtD
Cladribine—DCK—Diflorasone—Fluocinonide—psoriasis	8.86e-05	0.0179	CbGdCrCtD
Cladribine—DCK—Diflorasone—Beclomethasone—psoriasis	8.86e-05	0.0179	CbGdCrCtD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	8.82e-05	0.0013	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CAT—psoriasis	8.7e-05	0.00128	CbGpPWpGaD
Cladribine—DCK—Diflorasone—Fluocinolone Acetonide—psoriasis	8.61e-05	0.0174	CbGdCrCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.38e-05	0.00123	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—TYK2—psoriasis	8.36e-05	0.00123	CbGpPWpGaD
Cladribine—PNP—Flunisolide—Hydrocortisone—psoriasis	8.16e-05	0.0165	CbGdCrCtD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	8.06e-05	0.00119	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—PCNA—psoriasis	8.01e-05	0.00118	CbGpPWpGaD
Cladribine—POLA1—Norethindrone—Hydrocortisone—psoriasis	7.98e-05	0.0161	CbGdCrCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—psoriasis	7.8e-05	0.00115	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—PCNA—psoriasis	7.69e-05	0.00113	CbGpPWpGaD
Cladribine—PNP—Clobetasol propionate—Betamethasone—psoriasis	7.68e-05	0.0155	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Dexamethasone—psoriasis	7.68e-05	0.0155	CbGdCrCtD
Cladribine—PNP—Flunisolide—Dexamethasone—psoriasis	7.58e-05	0.0153	CbGdCrCtD
Cladribine—PNP—Flunisolide—Betamethasone—psoriasis	7.58e-05	0.0153	CbGdCrCtD
Cladribine—PNP—Metabolism—CAT—psoriasis	7.55e-05	0.00111	CbGpPWpGaD
Cladribine—PNP—Testosterone Propionate—Hydrocortisone—psoriasis	7.52e-05	0.0152	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Triamcinolone—psoriasis	7.5e-05	0.0151	CbGdCrCtD
Cladribine—PNP—Flunisolide—Triamcinolone—psoriasis	7.4e-05	0.0149	CbGdCrCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.39e-05	0.00109	CbGpPWpGaD
Cladribine—PNP—Fluticasone Propionate—Dexamethasone—psoriasis	7.31e-05	0.0148	CbGdCrCtD
Cladribine—PNP—Fluticasone Propionate—Betamethasone—psoriasis	7.31e-05	0.0148	CbGdCrCtD
Cladribine—RRM2—Cell Cycle—PCNA—psoriasis	7.16e-05	0.00105	CbGpPWpGaD
Cladribine—PNP—Fluticasone Propionate—Triamcinolone—psoriasis	7.15e-05	0.0144	CbGdCrCtD
Cladribine—Hepatobiliary disease—Methotrexate—psoriasis	7.13e-05	0.000355	CcSEcCtD
Cladribine—PNP—Clobetasol propionate—Prednisone—psoriasis	7.12e-05	0.0144	CbGdCrCtD
Cladribine—Gastrointestinal pain—Cyclosporine—psoriasis	7.11e-05	0.000354	CcSEcCtD
Cladribine—Dizziness—Mycophenolic acid—psoriasis	7.11e-05	0.000354	CcSEcCtD
Cladribine—Epistaxis—Methotrexate—psoriasis	7.11e-05	0.000354	CcSEcCtD
Cladribine—Paraesthesia—Prednisolone—psoriasis	7.11e-05	0.000354	CcSEcCtD
Cladribine—Tachycardia—Triamcinolone—psoriasis	7.1e-05	0.000354	CcSEcCtD
Cladribine—Mental disorder—Prednisone—psoriasis	7.09e-05	0.000353	CcSEcCtD
Cladribine—RRM1—Metabolism—CARM1—psoriasis	7.05e-05	0.00104	CbGpPWpGaD
Cladribine—Erythema—Prednisone—psoriasis	7.05e-05	0.000351	CcSEcCtD
Cladribine—Malnutrition—Prednisone—psoriasis	7.05e-05	0.000351	CcSEcCtD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	7.04e-05	0.00104	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.04e-05	0.000351	CcSEcCtD
Cladribine—Hyperhidrosis—Triamcinolone—psoriasis	7.03e-05	0.000351	CcSEcCtD
Cladribine—PNP—Flunisolide—Prednisone—psoriasis	7.03e-05	0.0142	CbGdCrCtD
Cladribine—NR5A1—Gene Expression—VDR—psoriasis	7e-05	0.00103	CbGpPWpGaD
Cladribine—Feeling abnormal—Mycophenolate mofetil—psoriasis	6.99e-05	0.000348	CcSEcCtD
Cladribine—Insomnia—Hydrocortisone—psoriasis	6.99e-05	0.000348	CcSEcCtD
Cladribine—PNP—Clobetasol propionate—Prednisolone—psoriasis	6.95e-05	0.014	CbGdCrCtD
Cladribine—Paraesthesia—Hydrocortisone—psoriasis	6.94e-05	0.000346	CcSEcCtD
Cladribine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.94e-05	0.000346	CcSEcCtD
Cladribine—Urticaria—Cyclosporine—psoriasis	6.91e-05	0.000344	CcSEcCtD
Cladribine—PNP—Fluocinolone Acetonide—Dexamethasone—psoriasis	6.89e-05	0.0139	CbGdCrCtD
Cladribine—PNP—Fluocinolone Acetonide—Betamethasone—psoriasis	6.89e-05	0.0139	CbGdCrCtD
Cladribine—Myalgia—Dexamethasone—psoriasis	6.89e-05	0.000343	CcSEcCtD
Cladribine—Myalgia—Betamethasone—psoriasis	6.89e-05	0.000343	CcSEcCtD
Cladribine—Abdominal pain—Cyclosporine—psoriasis	6.87e-05	0.000343	CcSEcCtD
Cladribine—Body temperature increased—Cyclosporine—psoriasis	6.87e-05	0.000343	CcSEcCtD
Cladribine—POLE—Cell Cycle—PCNA—psoriasis	6.87e-05	0.00101	CbGpPWpGaD
Cladribine—Anxiety—Betamethasone—psoriasis	6.86e-05	0.000342	CcSEcCtD
Cladribine—Anxiety—Dexamethasone—psoriasis	6.86e-05	0.000342	CcSEcCtD
Cladribine—PNP—Flunisolide—Prednisolone—psoriasis	6.86e-05	0.0138	CbGdCrCtD
Cladribine—Vomiting—Mycophenolic acid—psoriasis	6.83e-05	0.000341	CcSEcCtD
Cladribine—Discomfort—Dexamethasone—psoriasis	6.81e-05	0.000339	CcSEcCtD
Cladribine—Discomfort—Betamethasone—psoriasis	6.81e-05	0.000339	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—psoriasis	6.8e-05	0.000339	CcSEcCtD
Cladribine—Rash—Mycophenolic acid—psoriasis	6.78e-05	0.000338	CcSEcCtD
Cladribine—Dermatitis—Mycophenolic acid—psoriasis	6.77e-05	0.000337	CcSEcCtD
Cladribine—Pain—Prednisolone—psoriasis	6.77e-05	0.000337	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—psoriasis	6.76e-05	0.000337	CcSEcCtD
Cladribine—RRM2B—Metabolism—APOE—psoriasis	6.76e-05	0.000996	CbGpPWpGaD
Cladribine—Urticaria—Mycophenolate mofetil—psoriasis	6.74e-05	0.000336	CcSEcCtD
Cladribine—Headache—Mycophenolic acid—psoriasis	6.73e-05	0.000336	CcSEcCtD
Cladribine—PNP—Fluocinolone Acetonide—Triamcinolone—psoriasis	6.73e-05	0.0136	CbGdCrCtD
Cladribine—Decreased appetite—Hydrocortisone—psoriasis	6.72e-05	0.000335	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—psoriasis	6.71e-05	0.000334	CcSEcCtD
Cladribine—Body temperature increased—Mycophenolate mofetil—psoriasis	6.71e-05	0.000334	CcSEcCtD
Cladribine—Abdominal pain—Mycophenolate mofetil—psoriasis	6.71e-05	0.000334	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—psoriasis	6.68e-05	0.000333	CcSEcCtD
Cladribine—Gastrointestinal disorder—Hydrocortisone—psoriasis	6.67e-05	0.000332	CcSEcCtD
Cladribine—Fatigue—Hydrocortisone—psoriasis	6.66e-05	0.000332	CcSEcCtD
Cladribine—Urethral disorder—Methotrexate—psoriasis	6.63e-05	0.00033	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.63e-05	0.00033	CcSEcCtD
Cladribine—Pain—Hydrocortisone—psoriasis	6.61e-05	0.000329	CcSEcCtD
Cladribine—Oedema—Betamethasone—psoriasis	6.6e-05	0.000329	CcSEcCtD
Cladribine—Oedema—Dexamethasone—psoriasis	6.6e-05	0.000329	CcSEcCtD
Cladribine—Insomnia—Triamcinolone—psoriasis	6.58e-05	0.000328	CcSEcCtD
Cladribine—Infection—Dexamethasone—psoriasis	6.56e-05	0.000327	CcSEcCtD
Cladribine—Infection—Betamethasone—psoriasis	6.56e-05	0.000327	CcSEcCtD
Cladribine—Ill-defined disorder—Prednisone—psoriasis	6.54e-05	0.000326	CcSEcCtD
Cladribine—Paraesthesia—Triamcinolone—psoriasis	6.53e-05	0.000326	CcSEcCtD
Cladribine—Feeling abnormal—Prednisolone—psoriasis	6.52e-05	0.000325	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—NFKB1—psoriasis	6.52e-05	0.00096	CbGpPWpGaD
Cladribine—Anaemia—Prednisone—psoriasis	6.51e-05	0.000324	CcSEcCtD
Cladribine—Dyspnoea—Triamcinolone—psoriasis	6.49e-05	0.000323	CcSEcCtD
Cladribine—Nervous system disorder—Dexamethasone—psoriasis	6.48e-05	0.000323	CcSEcCtD
Cladribine—Nervous system disorder—Betamethasone—psoriasis	6.48e-05	0.000323	CcSEcCtD
Cladribine—Thrombocytopenia—Betamethasone—psoriasis	6.46e-05	0.000322	CcSEcCtD
Cladribine—Thrombocytopenia—Dexamethasone—psoriasis	6.46e-05	0.000322	CcSEcCtD
Cladribine—Tachycardia—Dexamethasone—psoriasis	6.44e-05	0.000321	CcSEcCtD
Cladribine—Tachycardia—Betamethasone—psoriasis	6.44e-05	0.000321	CcSEcCtD
Cladribine—Hypersensitivity—Cyclosporine—psoriasis	6.41e-05	0.000319	CcSEcCtD
Cladribine—Erythema multiforme—Methotrexate—psoriasis	6.4e-05	0.000319	CcSEcCtD
Cladribine—Nausea—Mycophenolic acid—psoriasis	6.38e-05	0.000318	CcSEcCtD
Cladribine—Hyperhidrosis—Betamethasone—psoriasis	6.38e-05	0.000318	CcSEcCtD
Cladribine—Hyperhidrosis—Dexamethasone—psoriasis	6.38e-05	0.000318	CcSEcCtD
Cladribine—Feeling abnormal—Hydrocortisone—psoriasis	6.37e-05	0.000317	CcSEcCtD
Cladribine—Malaise—Prednisone—psoriasis	6.35e-05	0.000317	CcSEcCtD
Cladribine—POLA1—Levonorgestrel—Hydrocortisone—psoriasis	6.35e-05	0.0128	CbGdCrCtD
Cladribine—Eye disorder—Methotrexate—psoriasis	6.32e-05	0.000315	CcSEcCtD
Cladribine—Gastrointestinal pain—Hydrocortisone—psoriasis	6.32e-05	0.000315	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	6.3e-05	0.000928	CbGpPWpGaD
Cladribine—Anorexia—Betamethasone—psoriasis	6.29e-05	0.000314	CcSEcCtD
Cladribine—Anorexia—Dexamethasone—psoriasis	6.29e-05	0.000314	CcSEcCtD
Cladribine—Urticaria—Prednisolone—psoriasis	6.29e-05	0.000313	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—psoriasis	6.28e-05	0.000313	CcSEcCtD
Cladribine—Fatigue—Triamcinolone—psoriasis	6.27e-05	0.000313	CcSEcCtD
Cladribine—PNP—Danazol—Hydrocortisone—psoriasis	6.25e-05	0.0126	CbGdCrCtD
Cladribine—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.25e-05	0.000311	CcSEcCtD
Cladribine—Asthenia—Cyclosporine—psoriasis	6.24e-05	0.000311	CcSEcCtD
Cladribine—PNP—Fluocinolone Acetonide—Prednisolone—psoriasis	6.24e-05	0.0126	CbGdCrCtD
Cladribine—Pain—Triamcinolone—psoriasis	6.22e-05	0.00031	CcSEcCtD
Cladribine—Hypotension—Dexamethasone—psoriasis	6.17e-05	0.000307	CcSEcCtD
Cladribine—Hypotension—Betamethasone—psoriasis	6.17e-05	0.000307	CcSEcCtD
Cladribine—Pruritus—Cyclosporine—psoriasis	6.15e-05	0.000307	CcSEcCtD
Cladribine—Urticaria—Hydrocortisone—psoriasis	6.14e-05	0.000306	CcSEcCtD
Cladribine—Angiopathy—Methotrexate—psoriasis	6.14e-05	0.000306	CcSEcCtD
Cladribine—Immune system disorder—Methotrexate—psoriasis	6.11e-05	0.000304	CcSEcCtD
Cladribine—Body temperature increased—Hydrocortisone—psoriasis	6.11e-05	0.000304	CcSEcCtD
Cladribine—Abdominal pain—Hydrocortisone—psoriasis	6.11e-05	0.000304	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—psoriasis	6.1e-05	0.000304	CcSEcCtD
Cladribine—Asthenia—Mycophenolate mofetil—psoriasis	6.09e-05	0.000303	CcSEcCtD
Cladribine—Chills—Methotrexate—psoriasis	6.07e-05	0.000302	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.07e-05	0.000894	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Betamethasone—psoriasis	6.02e-05	0.0003	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.02e-05	0.0003	CcSEcCtD
Cladribine—Pruritus—Mycophenolate mofetil—psoriasis	6e-05	0.000299	CcSEcCtD
Cladribine—Myalgia—Prednisone—psoriasis	6e-05	0.000299	CcSEcCtD
Cladribine—Arthralgia—Prednisone—psoriasis	6e-05	0.000299	CcSEcCtD
Cladribine—Feeling abnormal—Triamcinolone—psoriasis	6e-05	0.000299	CcSEcCtD
Cladribine—Anxiety—Prednisone—psoriasis	5.98e-05	0.000298	CcSEcCtD
Cladribine—Alopecia—Methotrexate—psoriasis	5.98e-05	0.000298	CcSEcCtD
Cladribine—Insomnia—Dexamethasone—psoriasis	5.97e-05	0.000298	CcSEcCtD
Cladribine—Insomnia—Betamethasone—psoriasis	5.97e-05	0.000298	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.96e-05	0.000297	CcSEcCtD
Cladribine—Diarrhoea—Cyclosporine—psoriasis	5.95e-05	0.000296	CcSEcCtD
Cladribine—Paraesthesia—Dexamethasone—psoriasis	5.93e-05	0.000295	CcSEcCtD
Cladribine—Paraesthesia—Betamethasone—psoriasis	5.93e-05	0.000295	CcSEcCtD
Cladribine—Discomfort—Prednisone—psoriasis	5.93e-05	0.000295	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—psoriasis	5.93e-05	0.000295	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—VEGFA—psoriasis	5.91e-05	0.000871	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PPARG—psoriasis	5.89e-05	0.000868	CbGpPWpGaD
Cladribine—Erythema—Methotrexate—psoriasis	5.89e-05	0.000293	CcSEcCtD
Cladribine—Malnutrition—Methotrexate—psoriasis	5.89e-05	0.000293	CcSEcCtD
Cladribine—PNP—Metabolism—APOE—psoriasis	5.86e-05	0.000864	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—STAT3—psoriasis	5.86e-05	0.000863	CbGpPWpGaD
Cladribine—Hypersensitivity—Prednisolone—psoriasis	5.83e-05	0.00029	CcSEcCtD
Cladribine—Diarrhoea—Mycophenolate mofetil—psoriasis	5.8e-05	0.000289	CcSEcCtD
Cladribine—RRM2—Metabolism—CARM1—psoriasis	5.8e-05	0.000855	CbGpPWpGaD
Cladribine—Urticaria—Triamcinolone—psoriasis	5.78e-05	0.000288	CcSEcCtD
Cladribine—Body temperature increased—Triamcinolone—psoriasis	5.75e-05	0.000287	CcSEcCtD
Cladribine—Dizziness—Cyclosporine—psoriasis	5.75e-05	0.000287	CcSEcCtD
Cladribine—Oedema—Prednisone—psoriasis	5.75e-05	0.000286	CcSEcCtD
Cladribine—Decreased appetite—Dexamethasone—psoriasis	5.74e-05	0.000286	CcSEcCtD
Cladribine—Decreased appetite—Betamethasone—psoriasis	5.74e-05	0.000286	CcSEcCtD
Cladribine—Infection—Prednisone—psoriasis	5.71e-05	0.000285	CcSEcCtD
Cladribine—Gastrointestinal disorder—Dexamethasone—psoriasis	5.7e-05	0.000284	CcSEcCtD
Cladribine—Gastrointestinal disorder—Betamethasone—psoriasis	5.7e-05	0.000284	CcSEcCtD
Cladribine—Back pain—Methotrexate—psoriasis	5.7e-05	0.000284	CcSEcCtD
Cladribine—Hypersensitivity—Hydrocortisone—psoriasis	5.69e-05	0.000284	CcSEcCtD
Cladribine—Fatigue—Betamethasone—psoriasis	5.69e-05	0.000284	CcSEcCtD
Cladribine—Fatigue—Dexamethasone—psoriasis	5.69e-05	0.000284	CcSEcCtD
Cladribine—Pain—Dexamethasone—psoriasis	5.65e-05	0.000281	CcSEcCtD
Cladribine—Pain—Betamethasone—psoriasis	5.65e-05	0.000281	CcSEcCtD
Cladribine—Nervous system disorder—Prednisone—psoriasis	5.64e-05	0.000281	CcSEcCtD
Cladribine—PNP—Norethindrone—Hydrocortisone—psoriasis	5.63e-05	0.0114	CbGdCrCtD
Cladribine—Tachycardia—Prednisone—psoriasis	5.61e-05	0.00028	CcSEcCtD
Cladribine—Dizziness—Mycophenolate mofetil—psoriasis	5.61e-05	0.000279	CcSEcCtD
Cladribine—Skin disorder—Prednisone—psoriasis	5.59e-05	0.000278	CcSEcCtD
Cladribine—Hyperhidrosis—Prednisone—psoriasis	5.56e-05	0.000277	CcSEcCtD
Cladribine—Asthenia—Hydrocortisone—psoriasis	5.54e-05	0.000276	CcSEcCtD
Cladribine—Vomiting—Cyclosporine—psoriasis	5.53e-05	0.000275	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	5.51e-05	0.000811	CbGpPWpGaD
Cladribine—Rash—Cyclosporine—psoriasis	5.48e-05	0.000273	CcSEcCtD
Cladribine—Anorexia—Prednisone—psoriasis	5.48e-05	0.000273	CcSEcCtD
Cladribine—Dermatitis—Cyclosporine—psoriasis	5.48e-05	0.000273	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—PCNA—psoriasis	5.48e-05	0.000807	CbGpPWpGaD
Cladribine—Pruritus—Hydrocortisone—psoriasis	5.47e-05	0.000272	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—psoriasis	5.46e-05	0.000272	CcSEcCtD
Cladribine—Headache—Cyclosporine—psoriasis	5.45e-05	0.000271	CcSEcCtD
Cladribine—Anaemia—Methotrexate—psoriasis	5.44e-05	0.000271	CcSEcCtD
Cladribine—Feeling abnormal—Betamethasone—psoriasis	5.44e-05	0.000271	CcSEcCtD
Cladribine—Feeling abnormal—Dexamethasone—psoriasis	5.44e-05	0.000271	CcSEcCtD
Cladribine—DCK—Metabolism—CARM1—psoriasis	5.42e-05	0.000799	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Dexamethasone—psoriasis	5.4e-05	0.000269	CcSEcCtD
Cladribine—Gastrointestinal pain—Betamethasone—psoriasis	5.4e-05	0.000269	CcSEcCtD
Cladribine—Vomiting—Mycophenolate mofetil—psoriasis	5.39e-05	0.000269	CcSEcCtD
Cladribine—PNP—Danazol—Prednisone—psoriasis	5.38e-05	0.0109	CbGdCrCtD
Cladribine—Hypersensitivity—Triamcinolone—psoriasis	5.36e-05	0.000267	CcSEcCtD
Cladribine—Rash—Mycophenolate mofetil—psoriasis	5.35e-05	0.000266	CcSEcCtD
Cladribine—Dermatitis—Mycophenolate mofetil—psoriasis	5.34e-05	0.000266	CcSEcCtD
Cladribine—Headache—Mycophenolate mofetil—psoriasis	5.31e-05	0.000265	CcSEcCtD
Cladribine—Malaise—Methotrexate—psoriasis	5.31e-05	0.000265	CcSEcCtD
Cladribine—Diarrhoea—Hydrocortisone—psoriasis	5.29e-05	0.000263	CcSEcCtD
Cladribine—Urticaria—Betamethasone—psoriasis	5.25e-05	0.000261	CcSEcCtD
Cladribine—Urticaria—Dexamethasone—psoriasis	5.25e-05	0.000261	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Prednisone—psoriasis	5.24e-05	0.000261	CcSEcCtD
Cladribine—Dizziness—Prednisolone—psoriasis	5.23e-05	0.000261	CcSEcCtD
Cladribine—ABCG2—Metabolism—NDUFA5—psoriasis	5.23e-05	0.00077	CbGpPWpGaD
Cladribine—Asthenia—Triamcinolone—psoriasis	5.22e-05	0.00026	CcSEcCtD
Cladribine—Body temperature increased—Dexamethasone—psoriasis	5.22e-05	0.00026	CcSEcCtD
Cladribine—Abdominal pain—Betamethasone—psoriasis	5.22e-05	0.00026	CcSEcCtD
Cladribine—Body temperature increased—Betamethasone—psoriasis	5.22e-05	0.00026	CcSEcCtD
Cladribine—Abdominal pain—Dexamethasone—psoriasis	5.22e-05	0.00026	CcSEcCtD
Cladribine—Insomnia—Prednisone—psoriasis	5.2e-05	0.000259	CcSEcCtD
Cladribine—SLC22A2—Metabolism—NDUFA5—psoriasis	5.17e-05	0.000762	CbGpPWpGaD
Cladribine—Nausea—Cyclosporine—psoriasis	5.17e-05	0.000257	CcSEcCtD
Cladribine—Paraesthesia—Prednisone—psoriasis	5.16e-05	0.000257	CcSEcCtD
Cladribine—Pruritus—Triamcinolone—psoriasis	5.15e-05	0.000257	CcSEcCtD
Cladribine—Cough—Methotrexate—psoriasis	5.14e-05	0.000256	CcSEcCtD
Cladribine—Dizziness—Hydrocortisone—psoriasis	5.11e-05	0.000255	CcSEcCtD
Cladribine—PNP—Metabolism—PPARG—psoriasis	5.11e-05	0.000752	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—TNF—psoriasis	5.07e-05	0.000747	CbGpPWpGaD
Cladribine—Nausea—Mycophenolate mofetil—psoriasis	5.04e-05	0.000251	CcSEcCtD
Cladribine—Chest pain—Methotrexate—psoriasis	5.01e-05	0.00025	CcSEcCtD
Cladribine—Myalgia—Methotrexate—psoriasis	5.01e-05	0.00025	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—psoriasis	5.01e-05	0.00025	CcSEcCtD
Cladribine—Decreased appetite—Prednisone—psoriasis	5e-05	0.000249	CcSEcCtD
Cladribine—Rash—Prednisolone—psoriasis	4.99e-05	0.000249	CcSEcCtD
Cladribine—Dermatitis—Prednisolone—psoriasis	4.98e-05	0.000248	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	4.98e-05	0.000248	CcSEcCtD
Cladribine—Fatigue—Prednisone—psoriasis	4.96e-05	0.000247	CcSEcCtD
Cladribine—Headache—Prednisolone—psoriasis	4.96e-05	0.000247	CcSEcCtD
Cladribine—Discomfort—Methotrexate—psoriasis	4.95e-05	0.000247	CcSEcCtD
Cladribine—Constipation—Prednisone—psoriasis	4.92e-05	0.000245	CcSEcCtD
Cladribine—Vomiting—Hydrocortisone—psoriasis	4.91e-05	0.000245	CcSEcCtD
Cladribine—POLA1—Cell Cycle—PCNA—psoriasis	4.9e-05	0.000721	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—PPARG—psoriasis	4.88e-05	0.000719	CbGpPWpGaD
Cladribine—Rash—Hydrocortisone—psoriasis	4.87e-05	0.000243	CcSEcCtD
Cladribine—Dermatitis—Hydrocortisone—psoriasis	4.87e-05	0.000243	CcSEcCtD
Cladribine—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	4.86e-05	0.000715	CbGpPWpGaD
Cladribine—Confusional state—Methotrexate—psoriasis	4.85e-05	0.000241	CcSEcCtD
Cladribine—Headache—Hydrocortisone—psoriasis	4.84e-05	0.000241	CcSEcCtD
Cladribine—SLC22A1—Metabolism—NDUFA5—psoriasis	4.82e-05	0.00071	CbGpPWpGaD
Cladribine—Dizziness—Triamcinolone—psoriasis	4.81e-05	0.00024	CcSEcCtD
Cladribine—SLC22A2—Transmembrane transport of small molecules—CP—psoriasis	4.81e-05	0.000708	CbGpPWpGaD
Cladribine—Infection—Methotrexate—psoriasis	4.77e-05	0.000238	CcSEcCtD
Cladribine—Feeling abnormal—Prednisone—psoriasis	4.74e-05	0.000236	CcSEcCtD
Cladribine—Asthenia—Dexamethasone—psoriasis	4.74e-05	0.000236	CcSEcCtD
Cladribine—Asthenia—Betamethasone—psoriasis	4.74e-05	0.000236	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	4.72e-05	0.000695	CbGpPWpGaD
Cladribine—Nervous system disorder—Methotrexate—psoriasis	4.71e-05	0.000235	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—psoriasis	4.71e-05	0.000234	CcSEcCtD
Cladribine—Gastrointestinal pain—Prednisone—psoriasis	4.7e-05	0.000234	CcSEcCtD
Cladribine—Nausea—Prednisolone—psoriasis	4.7e-05	0.000234	CcSEcCtD
Cladribine—Pruritus—Dexamethasone—psoriasis	4.67e-05	0.000233	CcSEcCtD
Cladribine—Pruritus—Betamethasone—psoriasis	4.67e-05	0.000233	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—psoriasis	4.67e-05	0.000233	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—psoriasis	4.65e-05	0.000231	CcSEcCtD
Cladribine—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	4.63e-05	0.000683	CbGpPWpGaD
Cladribine—Vomiting—Triamcinolone—psoriasis	4.63e-05	0.000231	CcSEcCtD
Cladribine—Nausea—Hydrocortisone—psoriasis	4.59e-05	0.000229	CcSEcCtD
Cladribine—Rash—Triamcinolone—psoriasis	4.59e-05	0.000229	CcSEcCtD
Cladribine—SLC22A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.59e-05	0.000675	CbGpPWpGaD
Cladribine—Dermatitis—Triamcinolone—psoriasis	4.58e-05	0.000228	CcSEcCtD
Cladribine—Anorexia—Methotrexate—psoriasis	4.58e-05	0.000228	CcSEcCtD
Cladribine—Urticaria—Prednisone—psoriasis	4.57e-05	0.000228	CcSEcCtD
Cladribine—Headache—Triamcinolone—psoriasis	4.56e-05	0.000227	CcSEcCtD
Cladribine—Body temperature increased—Prednisone—psoriasis	4.55e-05	0.000226	CcSEcCtD
Cladribine—Abdominal pain—Prednisone—psoriasis	4.55e-05	0.000226	CcSEcCtD
Cladribine—Diarrhoea—Betamethasone—psoriasis	4.52e-05	0.000225	CcSEcCtD
Cladribine—Diarrhoea—Dexamethasone—psoriasis	4.52e-05	0.000225	CcSEcCtD
Cladribine—Hypotension—Methotrexate—psoriasis	4.49e-05	0.000224	CcSEcCtD
Cladribine—PNP—Levonorgestrel—Hydrocortisone—psoriasis	4.48e-05	0.00904	CbGdCrCtD
Cladribine—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	4.48e-05	0.00066	CbGpPWpGaD
Cladribine—DCK—Desoximetasone—Hydrocortisone—psoriasis	4.48e-05	0.00903	CbGdCrCtD
Cladribine—ABCG2—Metabolism—CYP2S1—psoriasis	4.44e-05	0.000655	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP2S1—psoriasis	4.4e-05	0.000648	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Methotrexate—psoriasis	4.38e-05	0.000218	CcSEcCtD
Cladribine—Dizziness—Dexamethasone—psoriasis	4.37e-05	0.000218	CcSEcCtD
Cladribine—Dizziness—Betamethasone—psoriasis	4.37e-05	0.000218	CcSEcCtD
Cladribine—Insomnia—Methotrexate—psoriasis	4.35e-05	0.000217	CcSEcCtD
Cladribine—RRM1—Metabolism—CAT—psoriasis	4.33e-05	0.000638	CbGpPWpGaD
Cladribine—Nausea—Triamcinolone—psoriasis	4.32e-05	0.000215	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—psoriasis	4.32e-05	0.000215	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—psoriasis	4.28e-05	0.000213	CcSEcCtD
Cladribine—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	4.27e-05	0.00063	CbGpPWpGaD
Cladribine—Somnolence—Methotrexate—psoriasis	4.27e-05	0.000213	CcSEcCtD
Cladribine—Hypersensitivity—Prednisone—psoriasis	4.24e-05	0.000211	CcSEcCtD
Cladribine—Vomiting—Dexamethasone—psoriasis	4.2e-05	0.000209	CcSEcCtD
Cladribine—Vomiting—Betamethasone—psoriasis	4.2e-05	0.000209	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—psoriasis	4.18e-05	0.000208	CcSEcCtD
Cladribine—Rash—Dexamethasone—psoriasis	4.16e-05	0.000207	CcSEcCtD
Cladribine—Rash—Betamethasone—psoriasis	4.16e-05	0.000207	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.16e-05	0.000613	CbGpPWpGaD
Cladribine—Dermatitis—Betamethasone—psoriasis	4.16e-05	0.000207	CcSEcCtD
Cladribine—Dermatitis—Dexamethasone—psoriasis	4.16e-05	0.000207	CcSEcCtD
Cladribine—DCK—Desoximetasone—Dexamethasone—psoriasis	4.16e-05	0.00839	CbGdCrCtD
Cladribine—DCK—Desoximetasone—Betamethasone—psoriasis	4.16e-05	0.00839	CbGdCrCtD
Cladribine—Gastrointestinal disorder—Methotrexate—psoriasis	4.15e-05	0.000207	CcSEcCtD
Cladribine—Fatigue—Methotrexate—psoriasis	4.14e-05	0.000206	CcSEcCtD
Cladribine—Headache—Betamethasone—psoriasis	4.14e-05	0.000206	CcSEcCtD
Cladribine—Headache—Dexamethasone—psoriasis	4.14e-05	0.000206	CcSEcCtD
Cladribine—Asthenia—Prednisone—psoriasis	4.13e-05	0.000206	CcSEcCtD
Cladribine—Pain—Methotrexate—psoriasis	4.11e-05	0.000205	CcSEcCtD
Cladribine—SLC22A1—Metabolism—CYP2S1—psoriasis	4.1e-05	0.000604	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—IL6—psoriasis	4.09e-05	0.000603	CbGpPWpGaD
Cladribine—Pruritus—Prednisone—psoriasis	4.07e-05	0.000203	CcSEcCtD
Cladribine—DCK—Desoximetasone—Triamcinolone—psoriasis	4.06e-05	0.0082	CbGdCrCtD
Cladribine—DCK—Diflorasone—Dexamethasone—psoriasis	4.04e-05	0.00814	CbGdCrCtD
Cladribine—DCK—Diflorasone—Betamethasone—psoriasis	4.04e-05	0.00814	CbGdCrCtD
Cladribine—Feeling abnormal—Methotrexate—psoriasis	3.96e-05	0.000197	CcSEcCtD
Cladribine—DCK—Diflorasone—Triamcinolone—psoriasis	3.94e-05	0.00796	CbGdCrCtD
Cladribine—Diarrhoea—Prednisone—psoriasis	3.93e-05	0.000196	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—psoriasis	3.93e-05	0.000196	CcSEcCtD
Cladribine—Nausea—Dexamethasone—psoriasis	3.92e-05	0.000195	CcSEcCtD
Cladribine—Nausea—Betamethasone—psoriasis	3.92e-05	0.000195	CcSEcCtD
Cladribine—POLE2—Cell Cycle—TP53—psoriasis	3.92e-05	0.000578	CbGpPWpGaD
Cladribine—DCK—Desoximetasone—Prednisone—psoriasis	3.86e-05	0.00778	CbGdCrCtD
Cladribine—Urticaria—Methotrexate—psoriasis	3.82e-05	0.00019	CcSEcCtD
Cladribine—Dizziness—Prednisone—psoriasis	3.8e-05	0.000189	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—psoriasis	3.8e-05	0.000189	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—psoriasis	3.8e-05	0.000189	CcSEcCtD
Cladribine—DCK—Desoximetasone—Prednisolone—psoriasis	3.76e-05	0.00759	CbGdCrCtD
Cladribine—DCK—Diflorasone—Prednisone—psoriasis	3.74e-05	0.00755	CbGdCrCtD
Cladribine—Vomiting—Prednisone—psoriasis	3.66e-05	0.000182	CcSEcCtD
Cladribine—DCK—Diflorasone—Prednisolone—psoriasis	3.65e-05	0.00737	CbGdCrCtD
Cladribine—Rash—Prednisone—psoriasis	3.63e-05	0.000181	CcSEcCtD
Cladribine—Dermatitis—Prednisone—psoriasis	3.62e-05	0.00018	CcSEcCtD
Cladribine—Headache—Prednisone—psoriasis	3.6e-05	0.000179	CcSEcCtD
Cladribine—RRM2—Metabolism—CAT—psoriasis	3.57e-05	0.000526	CbGpPWpGaD
Cladribine—Hypersensitivity—Methotrexate—psoriasis	3.54e-05	0.000176	CcSEcCtD
Cladribine—Asthenia—Methotrexate—psoriasis	3.45e-05	0.000172	CcSEcCtD
Cladribine—Nausea—Prednisone—psoriasis	3.42e-05	0.00017	CcSEcCtD
Cladribine—Pruritus—Methotrexate—psoriasis	3.4e-05	0.000169	CcSEcCtD
Cladribine—RRM1—Metabolism—APOE—psoriasis	3.37e-05	0.000496	CbGpPWpGaD
Cladribine—DCK—Metabolism—CAT—psoriasis	3.34e-05	0.000491	CbGpPWpGaD
Cladribine—Diarrhoea—Methotrexate—psoriasis	3.29e-05	0.000164	CcSEcCtD
Cladribine—Dizziness—Methotrexate—psoriasis	3.18e-05	0.000158	CcSEcCtD
Cladribine—Vomiting—Methotrexate—psoriasis	3.06e-05	0.000152	CcSEcCtD
Cladribine—Rash—Methotrexate—psoriasis	3.03e-05	0.000151	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—psoriasis	3.03e-05	0.000151	CcSEcCtD
Cladribine—Headache—Methotrexate—psoriasis	3.01e-05	0.00015	CcSEcCtD
Cladribine—RRM1—Metabolism—PPARG—psoriasis	2.93e-05	0.000432	CbGpPWpGaD
Cladribine—Nausea—Methotrexate—psoriasis	2.85e-05	0.000142	CcSEcCtD
Cladribine—RRM2—Metabolism—APOE—psoriasis	2.77e-05	0.000409	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—psoriasis	2.63e-05	0.000388	CbGpPWpGaD
Cladribine—DCK—Levonorgestrel—Hydrocortisone—psoriasis	2.62e-05	0.00528	CbGdCrCtD
Cladribine—DCK—Metabolism—APOE—psoriasis	2.59e-05	0.000382	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—psoriasis	2.53e-05	0.000372	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PPARG—psoriasis	2.42e-05	0.000356	CbGpPWpGaD
Cladribine—DCK—Metabolism—PPARG—psoriasis	2.26e-05	0.000333	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CARM1—psoriasis	2.17e-05	0.00032	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CARM1—psoriasis	2.15e-05	0.000316	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CARM1—psoriasis	2e-05	0.000295	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—psoriasis	1.8e-05	0.000265	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CAT—psoriasis	1.33e-05	0.000197	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CAT—psoriasis	1.32e-05	0.000195	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CAT—psoriasis	1.23e-05	0.000181	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—APOE—psoriasis	1.04e-05	0.000153	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—APOE—psoriasis	1.03e-05	0.000151	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—APOE—psoriasis	9.57e-06	0.000141	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PPARG—psoriasis	9.03e-06	0.000133	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPARG—psoriasis	8.94e-06	0.000132	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPARG—psoriasis	8.33e-06	0.000123	CbGpPWpGaD
